icon-folder.gif   Conference Reports for NATAP  
 
  XVII International HIV Drug Resistance Workshop
June 10-14, 2008
Sitges, Spain
Back grey_arrow_rt.gif
 
 
 
Merck's Longitudinal Analysis of Resistance to the HIV-1 Integrase Inhibitor Raltegravir: Results from P005 a Phase 2 Study in Treatment Experienced Patients
 
 
  Reported by Jules Levin
XVII International HIV Drug Resistance Workshop
10-14JUN2008, Sitges, Spain
 
Michael D. Miller, Robert M. Danovich, Yuxiong Ke, Marc Witmer, Jing Zhao, Charlotte Harvey, Bach-Yen Nguyen, and Daria Hazuda for the P005 Study Team. Merck and Co, West Point PA 19486
 

geno-1.gif

Phase 2 Protocol 005 (treatment-experienced)
 
Patients with 3-class-resistance received Optimized Background Therapy (OBT) + raltegravir (200, 400, or 600 mg b.i.d.) or OBT + placebo
 
48 week efficacy: Virologic failure observed in 38/133 (28.6%) patients on RAL
 
Initial resistance analysis (cross-sectional): Integrase signature mutations were observed in 35 of 38 patients failing RAL, usually with other mutation(s)
 
Summary of phenotypic data (see poster)

-- Signature mutations (N155H, Q148H/K/R) confer >10-fold RAL resistance and reduce replication capacity
-- Secondary mutations consistently augment augment resistance, but have inconsistent effects on replication capacity
-- Q148 pathway has higher resistance than N155 pathway

week-2.gif

phenoe-3.gif

site-4.gif

PN-5.gif

accon-6.gif

Second-7.gif

oven-8.gif

cumul-9.gif